SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-39480 APPLIED UV, INC. (Exact name of registrant as specified in its charter) Delaware 84-4373308 (State or other jurisdiction of in ...

Applied UV, Inc. (NASDAQ:AUVI) Q4 2022 Earnings Conference Call April 3, 2023 9:00 AM ET Company Participants Brett Maas - Hayden IR Max Munn - Founder, CEO, President and Director Brian Stern - President of Puro Lighting Mike Riccio - CFO Conference Call Participants Chip Moore - EF Hutton Operator Greetings, and welcome to the Applied UV Fourth Quarter and Year End 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow ...

Title of Each Class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share AUVI The Nasdaq Stock Market LLC 10.5% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share AUVIP The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 Or ☐ TRANSITION REPOR ...

Applied UV, Inc. [AUVI] Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM ET Company Participants John Andrews - CEO Mike Riccio - CFO Max Munn - Founder, President & CEO of MunnWorks Brett Maas - Hayden IR Conference Call Participants Chip Moore - EF Hutton Operator Good morning, ladies and gentlemen, and welcome to the Applied UV 3Q 2022 financial results conference call. At this time, all participants have been placed on a listen-only mode. And we will open the floor for your questions and comme ...

Market Growth and Trends - The UV Disinfection market is projected to reach $9 billion by 2026, driven by increasing focus on infection control and improving technology [163]. - The global air purifier market is expected to grow from $9.24 billion in 2021 to approximately $22.84 billion by 2030, indicating strong demand for air purification solutions [164]. Company Performance - The Company reported total net sales of $5,907,646 for the three months ended June 30, 2022, compared to $1,884,320 for the same period in 2021, representing a significant increase [178]. - Net sales increased to $5,907,646 for the three months ended June 30, 2022, representing a 213.5% increase compared to $1,884,320 for the same period in 2021 [181]. - For the six months ended June 30, 2022, net sales totaled $9,263,736, compared to $4,196,935 for the same period in 2021 [186]. - Net sales for the six months ended June 30, 2022, were $9,263,736, an increase of $5,066,801 or 120.7% compared to $4,196,935 for the same period in 2021, driven by growth in both the Disinfection and Hospitality segments [188]. Profitability and Loss - Gross profit for the three months ended June 30, 2022, was $1,303,792, up from $533,229 in the same period of 2021 [178]. - Gross profit increased by $770,563 for the three months ended June 30, 2022, but gross profit as a percentage of sales decreased to 22.1% from 28.3% in Q1 2021 [182]. - The net loss for the three months ended June 30, 2022, was $2,888,655, an increase of $750,424 from a net loss of $2,138,231 for the same period in 2021 [184]. - Adjusted EBITDA loss for the three months ended June 30, 2022, was $(2,186,272), which was an increase of $(696,811) compared to the same period in 2021 [186]. - The total operating loss for the six months ended June 30, 2022, was $(5,959,116), compared to $(2,895,912) for the same period in 2021 [186]. - The company recorded a net loss of $4,538,527 for the six months ended June 30, 2022, compared to a net loss of $3,171,182 for the same period in 2021, reflecting increased S,G&A costs associated with business acquisitions [193]. Expenses and Costs - Selling, General, and Administrative (S,G&A) costs rose to $4,031,215 for the three months ended June 30, 2022, an increase of $1,332,733 compared to $2,698,482 in the same period in 2021 [183]. - Selling, General, and Administrative (S,G&A) expenses rose to $7,132,441 for the six months ended June 30, 2022, an increase of $2,832,442 compared to $4,299,999 in the same period in 2021, largely due to expansion and integration costs from recent acquisitions [190]. - Research and development expenses for the six months ended June 30, 2022, were $141,363, compared to $53,408 for the same period in 2021 [186]. - The Company incurred one-time costs of approximately $739,000 related to the integration of VisionMark operations and strategic marketing programs [183]. Cash Flow and Financing - Net cash used in operating activities was ($5,712,231) for the six months ended June 30, 2022, compared to ($3,398,543) in the same period in 2021, primarily due to the increased net loss [195]. - Cash provided by financing activities was $214,321 for the six months ended June 30, 2022, compared to cash used of ($67,101) in the same period in 2021, mainly due to the full exercise of a common stock offering [196]. - The company filed a shelf registration statement on July 1, 2022, to register $50,000,000 of securities, which may include common stock, preferred stock, and debt securities, to support its growth strategy [197]. Product Development and Partnerships - SteriLumen's Lumicide™ platform utilizes UVC LEDs to effectively kill pathogens in high-traffic areas, addressing healthcare-acquired infections [160]. - The Company has expanded its product portfolio to include air purification devices like Airocide™, which is FDA Class II Medical device and has applications across various sectors [161]. - SteriLumen's Scientific Air product has shown significant reductions in airborne pathogens in hospitals, contributing to effective infection prevention [162]. - The Company has signed distribution agreements in multiple regions, including exclusive rights for Airocide™ in the UAE, enhancing its global market presence [169]. - SteriLumen's product portfolio includes partnerships with recognized brands such as Walmart and Whole Foods, indicating strong market acceptance [168]. Future Outlook - The company anticipates efficiency gains in the coming year as it fully integrates its acquisitions and leverages synergies [190]. - The company has no off-balance sheet arrangements that could impact its financial condition or operations [199]. - Total contractual obligations amount to $2,785,911, with significant operating lease obligations of $1,598,343 due in the near term [198].

Acquisitions and Partnerships - The company acquired Akida Holdings LLC for $7.88 million, which had a revenue of approximately $4.7 million in 2020[15]. - The acquisition of KES for $4.3 million included contracts related to the Airocide™ air purification technologies, with KES generating approximately $4.5 million in revenue for the twelve months ended October 31, 2020[16]. - The company acquired Scientific Air Management for $9.5 million, which enhances its air purification portfolio for larger spaces[22]. - The company has established a licensing agreement with Axis Lighting to commercialize UVC devices for the hospital market, leveraging Axis's distribution network[37][38]. Product Development and Technology - Airocide™ technology has been cleared by the FDA as a class II medical device, suitable for critical hospital use cases[20]. - The Airocide™ system utilizes a proprietary titanium dioxide-based photocatalyst to eliminate airborne pathogens and is used by brands like DelMonte and Kroger[17]. - The Airocide™ product lines include APS for consumer units and GCS and HD lines for commercial applications, catering to various market needs[21]. - The company aims to integrate its products into a Data Driven Disinfection platform via the Clarity D3 app for smart asset management[25]. - The company aims to develop a Data Driven Disinfection platform to support safe environments during and after the pandemic, targeting large facilities in hospitality and sporting venues[27]. - The company is also focusing on healthcare facilities outside the hospital market, targeting infection prevention professionals and facilities with high infection rates[28]. - The Lumicide brand offers unique automated disinfecting systems using UVC LEDs, effective in killing pathogens, including SARS-CoV-2, with a focus on high-contamination surfaces[31][32]. - The company has five product lines incorporating Lumicide, including a disinfecting drain device and a disinfecting shelf, with additional products in development[34]. - The Clarity D3™ application enables IoT connectivity for real-time data transmission and asset management, enhancing operational efficiency[40]. Market Strategy and Expansion - The company plans to leverage Airocide's distribution capabilities to expand Scientific Air's products internationally, targeting the healthcare market[25]. - The company plans to expand its market opportunities to include airplane and cruise line bathrooms, schools, and upscale restaurants, emphasizing the importance of disinfection in these environments[29][30]. - The air purification market is competitive, and the company must manage risks related to supply chain and market perception[12]. Financial Health and Workforce - The company anticipates needing to raise additional capital to support its growth strategies and operations[12]. - The company has completed public offerings generating approximately $13.8 million from Series A Preferred Stock and $8 million from common stock, enhancing liquidity for operations and growth[42]. - Cash provided by financing activities in 2021 was $18.6 million, compared to cash used of $11.6 million in 2010, indicating improved financial health[257]. - As of December 31, 2021, the company had 61 employees, indicating a stable workforce to support its operations[44].